Whatever it takes to get us to NASDAQ is fine with me. If NASDAQ says RXMD needs a $4 share price, dividing the number of shares accordingly doesn't affect the company's value one bit.
RXMD is growing, and it's ridiculous to expect a small-but-growing company to have to increase their company value to $2 billion before uplisting, just because they issued 500 million shares back in the day. In this case, a reverse-split is just putting their house in order for the new stage they're about to appear on.
As the article I linked to previously said, if a NASDAQ company has to reverse-split in order to prevent delisting, that's a whole other matter, but it simply doesn't apply here with regards to RXMD.
News 
Market Data 
Discover 
